New malaria treatments show promise against drug-resistant strains
Two new malaria treatments are showing real hope in the fight against drug-resistant strains.
GanLum, a new medicine from Novartis, cured nearly 97% of patients in a big African trial—a little higher than the usual treatment.
Another option, a single-dose combo of four drugs, worked well for over 1,000 people in a study led in Gabon.
GanLum and single-dose combo could change malaria treatment game
GanLum isn't just effective—it also tackles tough, mutant parasites and helps stop the spread by targeting forms that transmit malaria.
The single-dose combo could make life easier for patients (no more three-day pill routines) and might help slow down resistance.
Treatments need approval, funding to reach patients
For these breakthroughs to actually reach people who need them most, they'll need regulatory approval and steady funding.
If that happens, these treatments could really change how malaria is fought in Africa—where it's still a huge health challenge.